Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Molecular Signature of the Pten Tumor Suppressor

a tumor suppressor and molecular signature technology, applied in the field of gene identification, can solve problems such as not being reported, and achieve the effect of predicting the effectiveness and/or responsiveness of a therapeuti

Inactive Publication Date: 2007-11-01
RGT UNIV OF CALIFORNIA
View PDF1 Cites 16 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0016] In one embodiment of present invention, a diagnostic and / or prognostic product comprising an antibody against the IGFBP2 provides diagnostic and / or prognostic value in associating tumor staging and grading in association with PTEN status.
[0020] In another embodiment of present invention, a diagnostic and / or prognostic product comprising an antibody against the IGFBP2 provides diagnostic and / or prognostic value in predicting the effectiveness and / or responsiveness of a therapeutics for treating human cancers.
[0021] In one embodiment of present invention, a diagnostic and / or prognostic product comprising a molecular probe in the forms of a nucleic acid molecule such as oligonucleotide, DNA and / or RNA molecule with its nucleotide sequence homologous or complementary to the gene sequence of the IGFBP2 gene provides diagnostic and / or prognostic value in associating tumor staging and grading in association with PTEN status.
[0023] In one embodiment of present invention, a diagnostic and / or prognostic product comprising a molecular probe in the forms of a nucleic acid molecule such as oligonucleotide, DNA and / or RNA molecule with its nucleotide sequence homologous or complementary to the gene sequence of the IGFBP2 gene provides diagnostic and / or prognostic value in predicting the effectiveness and responsiveness of a therapeutics for human cancers.

Problems solved by technology

However, its application to identify molecular signatures of a signal transduction pathway involved in tumor formation and progression has not been reported.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Molecular Signature of the Pten Tumor Suppressor
  • Molecular Signature of the Pten Tumor Suppressor
  • Molecular Signature of the Pten Tumor Suppressor

Examples

Experimental program
Comparison scheme
Effect test

example 1

Random Forest Deals Effectively with Microarray Data

[0077] We have used microarray technology to identify overexpression of androgen receptor as the general mechanism for hormone refractory prostate cancer. The data indicate that overexpression of androgen receptor is a diagnostic and therapeutic target for hormone refractory prostate cancer and can be used as a screening method for hormone refractory prostate cancer drug development (FIG. 7). This is consistent with microarray technology being a useful tool for a variety of purposes. However, it has been difficult in identifying molecular signatures for signal transduction pathways. One of the reasons is that microarray experiments are usually performed on a relatively few samples, therefore, data analysis on these experiments requires specific statistical tools. In this report, we described a novel unsupervised learning algorithm, called Random Forest, to identify a molecular signature for the signaling pathway of PTEN. This stat...

example 2

Molecular Signature of the PTEN Tumor Suppressor

[0078] To identify transcriptional targets associate with the PTEN tumor suppressor function, we compared the gene expression profiles of 11 tissue samples that have the wild-type PTEN gene to those of 14 samples that have mutated PTEN gene (table 1). These 25 samples include 12 advanced prostate cancer xenografts and 13 glioblastoma tissue samples. The PTEN status of the prostate cancer xenografts were characterized previously (21) and those of the glioblastoma were determined by western blot and genomic DNA sequence analysis. Six of the glioblastoma samples do not express the PTEN protein and, therefore, were defined as PTEN mutant samples. The other seven samples have the wild-type PTEN because they express the PTEN protein and they do not carry point mutation, which was determined by genomic DNA sequence analysis. We used both prostate cancer and glioblastoma tissue samples in order to increase a tissue-independent signature assoc...

example 3

Elevated Levels of IGFBP2 Expression in PTEN Mutant Tumors

[0080] Having identified several genes whose expression patterns correlate with the PTEN status, we wish to investigate biochemical regulation and biological role of one of these genes in PTEN function. Because both probe sets in the microarray were identified and both have the highest power in predicting the PTEN status, IGFBP2 was chosen for further study. As the first step, we confirmed the relationship between PTEN mutations and IGFBP2 expression by western blot analysis using whole tissue lysates from prostate cancer xenografts. IGFBP2 protein was detected in PTEN mutated xenografts LAPC9, LUCaP 35, and LNCaP but not in PTEN wild-type tumors LAPC4 and LUCaP23 (FIG. 2A, table 1), consistent with the microarray analysis.

[0081] The relationship was extended to other tumors that were not included in the microarray analysis. IGFBP2 was highly expressed in PTEN mutated tumors LAPC3, LAPC12, and LUCaP41, but was not detected ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Digital informationaaaaaaaaaa
Digital informationaaaaaaaaaa
Cell growthaaaaaaaaaa
Login to View More

Abstract

The present invention relates to the identification a molecular signature for PTEN tumor suppressor. The molecular signature comprising a gene or genes that are of use for diagnosis, prognosis, drug research and development and therapeutics. Specifically, the present invention relates to identification of IGFBP2 gene, its mRNA and / or protein products that closely associate with PTEN mutations. The present invention further demonstrates that IGFBP2 expression is negatively regulated by PTEN, positively regulated by PI3K and Akt activation, that IGFBP2 plays a functional role in the PTEN signaling and is required for Akt transformation. The use of IGFBP2 gene, its gene product such as its RNA transcript, protein and molecular probes in diagnosis, prognosis, drug discovery and validation and therapeutic target and therapeutics is also contemplated.

Description

BACKGROUND OF THE PRESENT INVENTION [0001] 1. Field of Invention [0002] The present invention relates to the identification of genes and their products including their coding protein products that are useful in diagnostics, prognostics and therapeutics of human tumors. In particular, the present invention relates to a set or sets of genes and their products that are associated with tumor suppressor gene PTEN abnormalities, such as PTEN gene deletions, loss of heterozygosity and / or mutations. The present invention relates further to genes and their products that are associated with PTEN-regulated cellular processes, in particular, the PI3K- and / or Akt signal transduction pathways and activations. [0003] 2. Description of Related Arts [0004] The PTEN / MMAC1 / TEP1 tumor suppressor gene was identified by genomic representational difference analysis (RDA) on human cancer tissues (1), by positional cloning to the genomic locus mutated in multiple advanced cancers (2), and by homologous sear...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395C12Q1/68C12N
CPCC12Q1/6886C12Q2600/136C12Q2600/118C12Q2600/112
Inventor CHEN CHARLIE D.SAWYERS CHARLES L.
Owner RGT UNIV OF CALIFORNIA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com